MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,818.93
+0.58%
NASDAQ 100
$31,224.47
+0.48%
DOW JONES
$51,521.00
+0.49%
NASDAQ Composite
$27,599.79
+0.45%
RUSSELL 2000
$2,813.40
-0.72%
CBOE VIX
$15.01
-3.29%

Sector Heatmap

Technology+0.53%
Financials+0.24%
Healthcare-0.17%
Consumer Cycl+1.20%
Consumer Staples+0.90%
Energy+0.47%
Industrials+0.87%
Materials+0.46%
Real Estate+1.06%
Utilities+2.98%
Comm Services+0.04%

NBIX — Neurocrine Biosciences Inc

Nasdaq

Neurocrine Biosciences Inc

CompareBack to Screener
$145.51
+1.30(+0.90%)
O
145.56
H
145.77
L
141.39
V
1.38M
⏱️ End-of-day dataAs of Oct 6, 2026

Chart

About NBIX

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateMay 23, 1996
Employees2,500
Stock ExchangeNasdaq
Ticker SymbolNBIX

Key Financial Statistics

Market Cap$14.55B
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$122.14 - $186.12
52-Week Avg Volume1.16M
VWAP$144.61
Transactions21,694
Total Recorded Bars7,640 days